Dr. Cytryn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 53rd St
New York, NY 10022Phone+1 212-639-2000
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2017 - 2020
Icahn School of Medicine at Mount SinaiClass of 2017
Certifications & Licensure
NY State Medical License 2019 - 2026
NJ State Medical License 2024 - 2025
CT State Medical License 2024 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer Start of enrollment: 2024 Feb 01
Roles: Contact
Publications & Presentations
PubMed
- Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.Lingyun Sun, Yun Xu, Nan Chen, Chunze Zhang, Aiwen Wu
European Journal of Cancer. 2024-12-01 - 1 citationsImmunotherapy for Resectable Locally Advanced Esophageal Carcinoma.Cameron N Fick, Elizabeth G Dunne, Smita Sihag, Daniela Molena, Samuel L Cytryn
The Annals of Thoracic Surgery. 2024-07-01 - 1 citationsPD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.Samuel J Klempner, Eric S Cowden, Samuel L Cytryn, Matteo Fassan, Hisato Kawakami
JCO Precision Oncology. 2024-06-01
Press Mentions
Bispecific Antibodies in Gastric Cancer: Big Questions but Bigger Potential?August 26th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
